CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
Chief Technology Officer Profile

Similar Companies

Canadian International Pharmacy Association

Canadian International Pharmacy Association is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SemBioSys Genetics

SemBioSys Genetics is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STIIIZY

STIIIZY is a cannabis lifestyle brand that offers premium quality cannabis products, including flower, extracts, vapes, pods, and weed delivery.

NeuroVia Inc.

Neurovia, Inc. operates in the pharmaceutical industry. The company was founded in 2013 and is based in San Francisco CA.

Dr. Reddy`s

Dr. Reddy`s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy`s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy`s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.